An orally administered quinolinium molecule mitigates neuropathology of Alzheimer’s disease through modulation of mitochondrial dysfunction and neuroinflammation
Cited by 0
Related Papers
Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer’s disease
|Drug Discovery Today|2024|15
Pharmacological interventions on GSK3β phosphorylation-mediated tau aggregation by modulating phase separation of tau proline-rich domain
|Biomedicine & Pharmacotherapy|2025|3
Evaluations of the neuroprotective effects of a dual-target isoquinoline inhibitor in the triple transgenic mouse model of Alzheimer's disease
|Neuroscience Letters|2023|1
Triple-Target Inhibition of Cholinesterase, Amyloid Aggregation, and GSK3β to Ameliorate Cognitive Deficits and Neuropathology in the Triple-Transgenic Mouse Model of Alzheimer’s Disease
|Neuroscience Bulletin|2025|1
Current mouse models of Alzheimer’s disease for investigating therapeutic agents
|Elsevier eBooks|2022|0